CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection Fraction The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)

Clinical TrialNov. 17, 2019

JOURNAL:Circulation. Article Link

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

MN Kosiborod, PJhund, KF Docherty et al. Keywords: dapagliflozin; HFrEF; quality of life; cardiovascular outcomes

FULL TEXT PDF